Brexit from the inside: MP’s views on how it will impact pharmaWith the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of Share XBrexit from the inside: MP’s views on how it will impact pharmahttps://pharmaphorum.com/views-and-analysis/brexit-inside-mps-views-impact-pharma/
US start-up launches bilingual healthcare appHoyHealth, an innovative health-tech start-up has launched HoyDoc, smartphone application that connects patients to medical providers through a Share XUS start-up launches bilingual healthcare apphttps://pharmaphorum.com/news/us-start-up-launches-bilingual-healthcare-app/
Pain Therapeutics’ opioid drug fails to gain FDA approvalThe US regulator has rejected Pain Therapeutics’ abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time. In a Share XPain Therapeutics’ opioid drug fails to gain FDA approvalhttps://pharmaphorum.com/news/opioid-drug-fails-gain-fda-approval/
Boehringer joins UK academics in battle against cystic fibrosisBoehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium announced a global collaboration to develop a Share XBoehringer joins UK academics in battle against cystic fibrosishttps://pharmaphorum.com/news/boehringer-battles-against-cystic-fibrosis/
NHS faces legal action over fertility treatment for gender transitioning patientsEngland’s NHS must offer transgender patients awaiting transitioning treatment access to fertility services, or face legal action according Share XNHS faces legal action over fertility treatment for gender transitioning patientshttps://pharmaphorum.com/news/nhs-fertility-treatment-gender-transitioning-patients/
EMA cuts services amid Brexit staff exodusEurope’s medicines regulator has said it is temporarily cutting services as it will lose at least 30% of Share XEMA cuts services amid Brexit staff exodushttps://pharmaphorum.com/news/ema-cuts-services-amid-brexit-staff-exodus/
Neurofibromatosis treatment granted orphan status by EMAAstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped Share XNeurofibromatosis treatment granted orphan status by EMAhttps://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/
New Huntington’s drug granted priority designationRoche’s treatment for Huntington’s disease has received a priority designation by the European regulator, sparking hope that a Share XNew Huntington’s drug granted priority designationhttps://pharmaphorum.com/news/huntingtons-drug-granted-priority-designation/
FDA grants leukaemia drug ‘breakthrough’ statusA leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that Share XFDA grants leukaemia drug ‘breakthrough’ statushttps://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/
